Similar articles

• [Serum CA 125 and TPA determination in malignant neoplasms of the uterus].

  Gadducci A, Facchini V, Bartolini T, Fioretti P. Gadducci A, et al. Ann Ostet Ginecol Med Perinat. 1988 May-Jun;109(3):151-5. Ann Ostet Ginecol Med Perinat. 1988. PMID: 3207319 Italian. No abstract available.
• [Importance of CA-50 detection in malignant gynecologic tumors].

  Indraccolo SR, Greco A, Cartechini MG, Compagnucci P. Indraccolo SR, et al. Minerva Ginecol. 1990 Dec;42(12):507-9. Minerva Ginecol. 1990. PMID: 2089292 Italian.
• [Detection of CA-125 antigen (non-mucinous ovarian cancer antigen)-- in serum of patients with gynecological malignancies].

  Sakamoto S, Kawana H, Shimizu K, Ishihara T, Ueda K, Usman SM, Uchida S, Kawagoe K, Kihara K, Kubo H. Sakamoto S, et al. Nihon Sanka Fujinka Gakkai Zasshi. 1984 Aug;36(8):1261-2. Nihon Sanka Fujinka Gakkai Zasshi. 1984. PMID: 6595322 Japanese. No abstract available.
• Tumor-associated antigens in gynecologic cancer.

  DiSaia PJ. DiSaia PJ. Clin Obstet Gynecol. 1975 Dec;18(4):87-108. doi: 10.1097/00003081-197512000-00008. Clin Obstet Gynecol. 1975. PMID: 765038 Review.
• Tumor antigenicity and the immune system in gynecological cancer: a review.

  Freedman RS, Bowen J, Herson J, Wharton JT, Rutledge FN. Freedman RS, et al. Gynecol Oncol. 1980 Feb;9(1):43-62. doi: 10.1016/0090-8258(80)90008-6. Gynecol Oncol. 1980. PMID: 6243598 Review. No abstract available.